|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2020-07-29 |
|
|
|
|
|
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
Phase II Trial of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke -- a Multi-center, Randomized, Double-blind, Parallel, Multi-doses and Active-controlled Study
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients.
富马酸西他沙星注射液治疗急性肾盂肾炎/复杂性尿路感染的有效性与安全性随机、盲法、阳性药物平行对照、多中心Ⅱ期临床研究
富马酸西他沙星注射液治疗急性肾盂肾炎/复杂性尿路感染的有效性和安全性,并探索最佳有效剂量。
A Randomized, Single Blind, Positive Parallel Controlled, Multicenter, Phase III Clinical Trial of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergencies
The purpose of this study was to determine the efficacy and safety of clevidipine for treating Hypertensive emergencies(defined as systolic blood pressure >180 mmHg and/or diastolic blood pressure >120 mmHg, accompanied by acute organ damage).
100 项与 南京优科生物医药研究有限公司 相关的临床结果
0 项与 南京优科生物医药研究有限公司 相关的专利(医药)
100 项与 南京优科生物医药研究有限公司 相关的药物交易
100 项与 南京优科生物医药研究有限公司 相关的转化医学